Advertisement

Topics

Ritter Pharmaceuticals Announces Phase 3 Plans after its End of Phase 2 Meeting with FDA on RP-G28 for Lactose Intolerance / Company has incorporated guidance from FDA on key elements of its Phase 3 program to support a New Drug Application (NDA) for RP-

09:31 EDT 18 Aug 2017 | FinanzNachrichten

LOS ANGELES, CA -- (Marketwired) -- 08/18/17 -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (the "Company"), a developer of novel therapeutic products that modulate the human gut microbiome to tre...

Original Article: Ritter Pharmaceuticals Announces Phase 3 Plans after its End of Phase 2 Meeting with FDA on RP-G28 for Lactose Intolerance / Company has incorporated guidance from FDA on key elements of its Phase 3 program to support a New Drug Application (NDA) for RP-

NEXT ARTICLE

More From BioPortfolio on "Ritter Pharmaceuticals Announces Phase 3 Plans after its End of Phase 2 Meeting with FDA on RP-G28 for Lactose Intolerance / Company has incorporated guidance from FDA on key elements of its Phase 3 program to support a New Drug Application (NDA) for RP-"

Advertisement
Quick Search
Advertisement
Advertisement